A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the ...
A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the ...
Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...
Neupro® (Rotigotine Transdermal System) is approved to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary restless legs syndrome ...
May 1, 2012 (New Orleans, Louisiana) — A transdermal patch that delivers 8 mg of the dopamine-receptor agonist rotigotine (Neupro, UCB) in a once-daily, single application is the lowest effective dose ...
* Announced today efficacy and safety data from a phase 3 study evaluating Neupro (rotigotine transdermal patch) in treatment of patients in china with early-stage Parkinson's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback